Glioblastoma is the most dangerous brain cancer. One reason for glioblastoma's aggressiveness are glioblastoma stem-like cells. To target them, a number of markers have been proposed (CD133, CD44, CD15, A2B5, CD36, CXCR4, IL6R, L1CAM, and ITGA6). A comprehensive study of co-expression patterns of them has, however, not been performed so far. Here, we mapped the multidimensional co-expression profile of these stemness-associated molecules. Gliomaspheres -an established model of glioblastoma stem-like cells -were used. Seven different gliomasphere systems were subjected to multicolor flow cytometry measuring the nine markers CD133, CD44, CD15, A2B5, CD36, CXCR4, IL6R, L1CAM, and ITGA6 all simultaneously based on a novel 9-marker multicolor panel developed for this study. The viSNE dimensionality reduction algorithm was applied for analysis. All gliomaspheres were found to express at least five different glioblastoma stem-like cell markers.
| INTRODUCTION
Glioblastoma is the most aggressive and most frequent malignant brain tumor in adults. 1 Classical treatment comprising surgery, radiotherapy, and chemotherapy is only temporarily effective. The median survival in adult patients is less than 2 years.
One reason for glioblastoma's resistance to a number of therapies is the presence of stem-like glioblastoma cells. 2 Despite initial hesitation in the scientific community towards a concept of stem-like cells in glioblastoma, they are now mainly accepted as existent. [3] [4] [5] [6] [7] These stem-like cells share a transcriptional profile with neural stem cells. 8 Similar to how neural stem cells grow as neurospheres in vitro, glioblastoma stem-like cells grow as "gliomaspheres" in vitro.
These gliomaspheres resemble the original tumor more than traditional adherent cell culture of glioblastoma cells does. 9 Glioblastoma stem-like cells have first been described by Singh et al in 2004 . 10 To prove stemness of stem-like cells, xenotransplantation experiments were performed showing that as little as 100 cells could initiate tumor formation in NOD-SCID mouse brains. To identify stem-like cells, Singh et al used the surface marker CD133. Since then, CD133 has become the most studied marker for glioblastoma stem-like cells. It has been connected to radioresistance. 2 It has been shown to be essential for stem cell maintenance. 11 It has been visualised in positron emission tomography to monitor stem-like glioblastoma cells. 12 And it has been connected spatially and functionally to perivascular stem cell niches 13, 14 or hypoxic niches. 15 There was, however, also controversy regarding its suitability as a marker to unambiguously identify glioblastoma stem-like cells. 16 Therefore, also other potential markers have been investigated and discussed. An association with stemness has been established for a number of them in glioblastoma: A2B5, a glial progenitor cell marker, has been shown to identify glioblastoma cells with stem-like properties. 17, 18 L1CAM is evidently necessary for the maintenance and survival of glioblastoma stem-like cells in vivo and in vitro.
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CXCR4 is overexpressed in glioblastoma stem-like cells as opposed to bulk glioblastoma cells 20 and its inhibition reduces the selfrenewal capacity of glioblastoma stem-like cells. 21 CD15 (SSEA-1, Lewis X) has been shown to be an enrichment factor for glioblastoma stem-like cells. 22 IL6R (Interleukin-6 receptor) is preferentially expressed on glioblastoma stem-like cells and targeting it via eg short hairpin RNAs (shRNAs) reduces gliomasphere formation capacity. 23 CD44 has been implicated with the perivascular stem cell niche and a cell population enriched with glioblastoma stem-like cells. 24 Also, CD44 signaling can enhance glioblastoma stem-like cell phenotypes. 25 ITGA6 (Integrin alpha-6) has been identified as a glioblastoma stem-like cell enrichment marker and a potential therapeutic target. 26 Apart from that, ITGA6 inhibition is necessary for some forms of glioblastoma stemness suppression. 27 CD36 is specific for glioblastoma stem-like cells and drives glioblastoma progression. 28 All in all, nine different surface molecules (CD133, A2B5, L1CAM, CXCR4, CD15, IL6R, CD44, ITGA6 and CD36) have repeatedly been associated with glioblastoma stem-like cells in the literature. These nine molecules are consistently summarised as a particularly relevant set of stemness-related markers in glioblastoma -eg by Sundar et al and by Brescia et al. [29] [30] [31] [32] [33] That is why we chose to focus on these nine markers.
While individual marker expression has been extensively studied 34 That study, however, did not focus on stemness markers specific for glioblastoma but rather used a generic stemness marker panel. To our knowledge, there is so far no comprehensive study on the nine stemness markers specifically identified in glioblastoma and their respective co-expression. To date, this represents a relevant gap in the neuroscientific landscape of glioblastoma stemness markers and how they are interrelated.
The objective of our research efforts was thus to address the present gap via introducing high-dimensional measurement techniques and to establish co-expression patterns of these 9 relevant glioblastoma stemness markers ( Figure S1 ). We decided to approach the goal via the in vitro-study of gliomaspheres combined with a multicolor flow cytometry antibody panel comprising all nine glioblastoma stem-like cell molecules at once. Felzmann & C. Marosi, data currently being submitted).
To integrate the 9-dimensional flow cytometry data, we used the viSNE algorithm 38 that condenses multi-dimensional information to two dimensions, which can then be visualised.
The question of a potential clinical importance of observed marker combinations was subsequently studied using The
Cancer Genome Atlas (TCGA) datasets. Also, we illustrated the biological pathways typical for the most common stem-like cell marker combination via eg the Database for Annotation, Visualization and Integrated Discovery (DAVID) bioinformatics system.
As a result, we successfully mapped the hitherto unknown coexpression combinatorics of 9 stemness-associated markers. This led to the discovery of a novel marker combination (CD44+/CD133+/ ITGA6+/CD36+) found consistently on all studied model systemsproving the practicability, utility and relevance of multidimensional approaches for studying gliomaspheres. 
| Gliomasphere culture
Gliomaspheres were generated in analogy to well established standard protocols. 37, [39] [40] [41] Briefly, glioblastoma cells were transferred from T75
to T25 flasks (to facilitate cell-cell contacts) with serum-free media supplemented with growth factors -as typically used for a spheric pheno- Table S1 .
| Instrumentation
7-AAD was used as viability dye. Additionally, unstained controls as well as appropriate human isotype controls were added to the panel according to the manufacturer's recommendations.
| Data interpretation and definition of "positive" markers
Cytometer measurements were analysed using FlowJo V10. A difference of at least 10% in the mean fluorescence intensity (MFI) values between epitope-specific antibodies and isotype antibodies in combination with a visually distinguishable shift of the histogram was considered a "positive" staining.
| viSNE analysis
The viSNE dimensionality reduction tool was used to visualise multidimensional surface molecule expression patterns on a single cell basis. Data were analysed in MatLab (MathWorks, Natick, MA, USA)
to create a viSNE map that relies on minimizing differences between high-and low-dimensional spaces and produces a 2-dimensional plot.
Briefly, a pairwise distance matrix is calculated in high dimensional space, which is transformed to a similarity matrix using a Gaussian kernel. The points are randomly mapped in low-dimensional space and iteratively rearranged to minimise the divergence between highand low-dimensional similarity matrices.
| TCGA analysis of GBM patient cohorts
In order to estimate the clinical relevance of our stem-like cell signa- 
| Statistical analyses
The log-rank test was used for comparison of survival curves.
P < 0.05 were considered significant. All statistical analyses were carried out with the GraphPad Prism V5 software for Windows (GraphPad, San Diego, CA, USA).
3 | RESULTS 3.1 | Single-color staining of nine molecules: All 7
gliomaspheres examined express at least 5 stemness-associated markers
As a first step, we evaluated the single-color marker expression of the nine stemness-associated molecules on all seven gliomaspheres. Positivity of a marker was defined as an increase in MFI of at least 10% compared with the isotype antibody (or unstained cells in the case of CD36) plus a visually identifiable shift of the histogram. Both criteria had to be met. Figure 1 depicts the single-marker analysis of NCH644 gliomaspheres as an example. Single-color analysis of cells stained with epitopespecific antibodies (vs cells stained with isotype antibodies) indicates that all seven gliomaspheres have the capacity to express at least five stemness-associated markers (Table 1 and Table S2 ). NCH421K and NCH644 gliomaspheres showed the highest number of markers as they were positive for eight surface molecules (A2B5, CD15, CD44, CD133, CXCR4, ITGA6, L1CAM, CD36) and only negative for IL6R. The gliomaspheres expressing the lowest number of just five molecules were Linz1 and Gli16. Linz2, U87MG and U251MG expressed 6 different stemnessassociated molecules. Of the nine molecules evaluated, eight were found on at least one gliomasphere model. IL6R was the only molecule not present on any of the seven gliomasphere models.
3.2 | Single-color staining of nine molecules: The most frequent set of markers present is CD44, CD133, ITGA6 and CD36
When looking at the most abundant combination of factors in this single-color analysis, we found that the set of markers expressed most often was CD44, CD133, ITGA6 and CD36. Of the seven gliomasphere models, this combination could be observed in all of them in at least one measurement (Table 1) . Hence, all gliomasphere models shared the same minimal combination of markers.
As single-color flow cytometry does not allow conclusions about the co-expression of specific markers by a specific subset of cells, we proceeded to perform a multi-color staining to address this issue.
3.3 | Multi-color staining of nine molecules: All possible double-marker combinations are detectable
As the first step of the multi-color analysis, we investigated the existence of double-positive populations. As depicted in Table   S3 , all theoretical double-marker combinations of the eight measurable markers (except for IL6R) could be found in at least one of the seven gliomasphere systems. Overall, of the 232 possible gliomasphere-specific combinations based on the previous single-color measurement (Table S3) , only 16 (6.9%) were not detectable.
3.4 | Multi-color staining of nine molecules: The core signature CD44+/CD133+/ITGA6+/CD36+ is present in all 7 gliomaspheres
As a next step, we looked at the multidimensional multicolor data going beyond double-positive combinations. We discovered that the ingly, while all 7 gliomasphere models showed this core sub-population, additionally, in five of them the core population was also positive for at least one further marker ( Table 2 ). The exact gating process for all further gliomasphere models apart from NCH644 is depicted in Figures S2-S7. 3.5 | Multi-color staining of nine molecules:
Integrated multidimensional analysis via the viSNE algorithm confirms the CD44+/CD133+/ITGA6+/ CD36+ signature in all 7 gliomaspheres
To integrate the 9-dimensional marker information measured through multi-color staining also by automatic analysis, we used the viSNE algorithm. It reduces multiple dimensions to two dimensions of "similarity." Single markers can then be depicted as a third axis and a fourth marker can be visualised through color coding of intensity (shown for NCH644 in Figure 3 ). Across all of the seven gliomaspheres examined we could confirm the existence of the previously identified core signature (data not shown). We consistently found a population of cells with high-intensity color coding of the markers CD44, CD133, CD36, and ITGA6 (shown for NCH644 in Figure 3 as an example). 3.7 | In silico pathway analysis: Cell adhesion is among the biological processes connected to the CD44+/CD133+/ITGA6+/CD36+ signature Then, we investigated the potential biological meaning of the identified marker combination. The DAVID analysis indicated that "cell adhesion," "cell-matrix adhesion," and "ECM-receptor interaction" are among the biological processes typical for the core combination (Table 3) .
Also, we studied interaction pathways with the help of the PCViz that summarises findings from the literature. When entering the four signature genes, focusing on state change control interactions and zooming in on the 200 most relevant genes, we arrived at the interactome depicted in Figure S8 . Apparently, Protein kinase C α (PRKCA) is a molecule that interacts with ITGA6, CD36 und CD44, while CD133 is not linked to PRKCA. When examining the relation to IDH1 status, we registered that the CD44+/CD133+/ITGA6+/CD36+ signature was significantly higher in IDH1 wild-type patients than in IDH1-mutated patients (P < 0.001) -in both datasets (see Figure S9 ). The main overall finding is that feasibility, utility and relevance of a multidimensional approach to gliomasphere research are shown here.
| Limitations of the study
This study focused on establishing high-dimensional flow cytometry for gliomasphere research. In doing so, we measured the full set of possible marker combinations, detected a novel signature and char- 
| "Stemness" of the cell systems we used
Are the cells we used really "stem cells"? In our view it is unjustifiable and exaggerated to directly regard gliomaspheres as "stem missing -which is why we call them "spheres" and never "stem cells" or "stem-like cells."
Cells harbouring the CD44+/CD133+/ITGA6+/CD36+ signature were consistently found in gliomasphere cells from all these sources in our study -of which the majority (4/7) were pre-established stemness models. It is, thus, justifiable to see the identified molecule combination as a potentially dominant consensus signature.
Given that we had deliberately focused on molecules already connected to glioblastoma stemness in the literature, it seems legitimate to regard the CD44+/CD133+/ITGA6+/CD36+ signature as "stemness-associated." All markers had already individually been described as stemness-related, 29, 30, 32, 33 which is why they were chosen. The signature was detectable on all cells, including those with a previously reported "stem-like" nature in vivo (NCH421K, NCH644).
Summing up, we deduct that a combination of markers with proven "stemness"-properties measured on proven "stemness"-models can then be also "stemness"-related. Nothing more but also nothing less.
In terms of exact data interpretation, we still continuously call the identified marker combination the "CD44+/CD133+/ITGA6+/CD36+
signature" and not the "stemness signature" or anything similar. T A B L E 2 Multi-color staining results of the 9 stem cell markers in the 7 gliomasperes. In all 7 gliomaspheres, we could find a cellular population positive for the core signature CD44/CD133/CD36/ ITGA6. In selected gliomaspheres, the cells from the core signature were in addition also positive for further markers Nevertheless, the finding that an enrichment of the signature molecules in the full tissue system is survival-related is still of interest. It indicates that the signature identified might be indeed connected to a more "aggressive" whole-system phenotype -eg due to a more stem-like nature of the tissue. All functional considerations (see above) are, however, still purely speculative at that stage.
Future research will have to clarify that aspect -and whether the signature is also present on single glioblastoma cells in vivo. For the latter, it will be eg useful to stain tissue sections with multiple markers.
F I G U R E 3
Results of the viSNE multidimensional algorithm analysis as shown for NCH644. The viSNE algorithm reduces multiple dimensions to two dimensions ("bh-SNE1" and "bh-SNE2") that indicate the overall similarity of cells. The graphs show as a third (z-)axis the expression of CD44. The color coding indicates the intensity of further markers and which cellular population is enriched. The algorithm clearly identifies the core stem-like cell population as a distinct population
| Preliminary implications of in silico findings
Our observation in the DAVID analysis that the pathways with an enrichment of the core signature markers are eg "cell adhesion" or "cell-matrix adhesion" is much in line with the very nature of gliomaspheres. For the formation of spheres, "cell adhesion" is required.
Thus, the signature molecules might be contributing to the spheric geometry that gliomapheres show. And "cell-matrix adhesion" fits the fact that glioblastoma stem-like cells are typically found in perivascular niches. 15 In silico prediction indicated a potential role of PRKC -in line with complementary observations by others: PRKC phosphorylates CD36 and thereby blocks binding of Thrombospondin-1 in melanoma cells. 52 It changes phosphorylation patterns of CD44 that result in alterations of cell motility. 53 Regarding ITGA6, PRKC is necessary for the chemotactic migration of (squamous) carcinoma cells via its ability to mobilize ITGA6B4 from hemidesmosomes. 54 While the subtype analysis was inconclusive in our view, the IDH1 observations are of specific interest: the CD44+/CD133+/ ITGA6+/CD36+ signature seems associated with IDH1 wildtype status -and so a more aggressive phenotype.
To date, however, all these in silico-based considerations are purely speculative and warrant further investigation.
| CONCLUSION
Summing up, the present study adds a fresh perspective to a wellstudied field. Its mapping of co-expression combinatorics and its finding of a CD44+/CD133+/ITGA6+/CD36+ molecule signature on F I G U R E 4 Core signature expression significantly correlates with a poor patient survival. A total of 2 different sized datasets, the MIT/ Harvard (Affymetrix) cohort and the University of North Carolina (Agilent) cohort, were extracted from the open source The Cancer Genome Atlas and analysed for the core signature expression CD133+/CD36+/CD44+/ITGA6+ or all 9 markers (less the ganglioside A2B5 that is not measured in gene expression datasets). ***P < 0.001, **P < 0.01, *P < 0.05 gliomaspheres is a relevant step towards a more complete understanding of stemness-associated molecules in glioblastoma. 
